We are live on ! Find out more
NWBO

Northwest Biotherapeutics
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

70 hedge funds and large institutions have $78.2M invested in Northwest Biotherapeutics in 2014 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 12 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 12

6.88% more ownership

Funds ownership: 13.89% → 20.77% (+6.9%)

1% less funds holding

Funds holding: 71 → 70 (-1)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

38% less call options, than puts

Call options by funds: $2.31M | Put options by funds: $3.74M

41% less capital inflows, than outflows

Capital inflows: $5.62M | Capital outflows: $9.6M

Holders
70
Holders Change
-1
Holders Change %
-1.41%
% of All Funds
1.86%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
8
Increased
26
Reduced
12
Closed
11
Calls
$2.31​M
Puts
$3.74​M
Net Calls
-⁠$1.43​M
Net Calls Change
+$1.18​M

NWBO Hedge Fund Activity: Q4 2014 in Review

70 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics (NWBO) for Q4 2014, worth a combined $78.2M — up 80% from $43.5M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of NWBO and 8 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 26 added.

The largest buyer was Goldman Sachs, adding an estimated $1.17M. The largest seller was Franklin Resources, exiting entirely with an estimated $5.16M sold.

  • 70 institutional investors held Northwest Biotherapeutics (NWBO) as of Q4 2014, down from 71 in Q3 2014.
  • Funds reported $78.2M of Northwest Biotherapeutics stock for Q4 2014, up 80% quarter-over-quarter.
  • 8 funds opened new Northwest Biotherapeutics positions in Q4 2014 and 11 closed out, a net change of -3 holders.
  • The largest Northwest Biotherapeutics buyer in Q4 2014 was Goldman Sachs, an estimated $1.17M added.
  • The largest Northwest Biotherapeutics seller in Q4 2014 was Franklin Resources, an estimated $5.16M sold.

Based on aggregated 13F filings for Q4 2014.